- Completed $16 million equity financing in February
- Appointed Christopher Kiritsy as President and Chief Executive Officer
- Changed name from Triad Pharmaceuticals, Inc. to Arisaph Pharmaceuticals, Inc.
- Presented preclinical data showing significant plaque regression with rev D-4F at American Heart Association meeting
- Received issuance of broad combination therapy patent in U.S. (No. 6,890,898)
- Raised significant non-dilutive capital by leveraging diabetes IP
- Extended cardiovascular drug discovery partnership with Abbott Laboratories
- Established research collaboration with Fox Chase Cancer Center
- Established Scientific Advisory Board, consisting of renowned experts in CV, endocrinology and oncology
- Filed IND for DPP IV inhibitor to treat type 2 diabetes
- Completed first-in-man Phase 1a clinical trial of DPP IV inhibitor in healthy subjects
- Raised significant non-dilutive capital by leveraging diabetes IP
- Presented data at June ADA meeting showing DPP IV inhibitor possesses a beneficial DPP IV independent mechanism
- Synthesized and selected lead Niacin analog
- Completed manufacture, fill and stability of clinical supplies for Niacin analog
- Completed IND enabling preclinical studies for Niacin analog
- Established additional collaboration with experts in oncology
- Unified exclusive patent estate for use of DPP 4 inhibitors in Type 1 diabetes
- Awarded $2.8 million from the U.S. government under the Therapeutics Discovery Project Program (TDPP); 2nd highest out of nearly 3,000 awarded recipients
- Received favorable scores on two phase 1 STTR oncology grant applications; one of which achieved a perfect score
- Relocated corporate headquarters to 100 High Street in Boston; the heart of the financial district
- Filed IND for Niacin analog to treat mixed dyslipidemia
- Initiated first-in-man Phase 1a clinical trial of Niacin analog in healthy subjects
- Raised $17 million in non-dilutive funds by monetizing a DPP-IV license agreement
